Objective: To assess the risk of hysterectomy after nonresectoscopic endometrial ablation in patients with heavy menstrual bleeding.
Data Sources: The EMBASE, MEDLINE, ClinicalTrials.gov and Cochrane databases were searched for eligible articles from inception until June 13, 2022. We used combinations of search terms for endometrial ablation and hysterectomy.
Methods Of Study Selection: Articles included in the review described the incidence of hysterectomy at a specific point in time after ablation with a minimum follow-up duration of 12 months.
Tabulation, Integration, And Results: The literature search yielded a total of 3,022 hits. A total of 53 studies met our inclusion and exclusion criteria, including six retrospective studies, 24 randomized controlled trials, and 23 prospective studies. A total of 48,071 patients underwent endometrial ablation between 1992 and 2017. Follow-up duration varied between 12 and 120 months. Analyses per follow-up moment showed 4.3% hysterectomy rate at 12 months of follow-up (n=29 studies), 11.1% at 18 months (n=1 study), 8.0% at 24 months (n=11 studies), 10.2% at 36 months (n=12 studies), 7.6% at 48 months (n=2 studies), and 12.4% at 60 months (n=6 studies). Two studies reported a mean hysterectomy rate at 10 years after ablation of 21.3%. Minimal clinically relevant differences in hysterectomy rates were observed among the different study designs. Furthermore, we found no significant differences in hysterectomy rate among the different nonresectoscopic endometrial ablation devices.
Conclusion: The risk of hysterectomy after endometrial ablation seems to increase from 4.3% after 1 year to 12.4% after 5 years. Clinicians can use the results of this review to counsel patients about the 12% risk of hysterectomy 5 years after endometrial ablation.
Systematic Review Registration: PROSPERO, CRD42020156281.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/AOG.0000000000005223 | DOI Listing |
Objective: To determine the changes in procedural utilization for symptomatic uterine fibroids and adenomyosis over the past decade.
Methods: An IRB-exempt retrospective study of the National Inpatient Sample database from 2011-2020 was performed utilizing ICD-9 and 10 diagnosis and procedural codes for uterine fibroids, adenomyosis, hysterectomy, myomectomy, UAE, and endometrial ablation. Patients with endometriosis, uterine cancer, placenta accreta spectrum, pelvic inflammatory disease, and uterine prolapse were excluded.
J Osteopath Med
December 2024
Department of Medical and Surgical Gynecology, Mayo Clinic, Phoenix, AZ, USA.
Biol Reprod
November 2024
Department of Reproductive center, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
The placenta, serving as the crucial link between maternal and infant, plays a pivotal role in maintaining a healthy pregnancy. Placental dysplasia can lead to various complications, underscoring the importance of understanding trophoblast lineage development. During peri-implantation, the trophectoderm (TE) undergoes differentiation into cytotrophoblast (CTB), syncytiotrophoblast (STB), and extravillous trophoblast (EVT).
View Article and Find Full Text PDFJ Vasc Interv Radiol
November 2024
Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts.
Purpose: To evaluate oncological outcomes, abscopal effect, and adverse events (AEs) of pulsed electrical field (PEF) ablation of tumors in the chest, abdomen, and pelvis.
Materials And Methods: PEF ablations performed at an academic medical center between May 2023 and January 2024 were retrospectively analyzed. Eleven patients (4 males and 7 females; age, 58 years ± 19) underwent 11 PEF sessions targeting 13 tumors (lung metastasis from solitary fibrous tumor [n = 3] and colorectal carcinoma (CA) [n = 1], osteosarcoma pleural metastases [n = 2], hepatocellular CA [n = 2], liver metastasis from colorectal CA [n = 1] and leiomyosarcoma [n = 1], metastatic melanoma to the pancreas [n = 1], metastatic retroperitoneal lymph node from endometrial CA [n = 1], and recurrence of endometrial CA in the vaginal cuff [n = 1]) with the goal of complete coverage (n = 11/13) or debulking (n = 2/13).
Sci Transl Med
November 2024
Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.
Endometriosis is a debilitating and painful gynecological inflammatory disease affecting up to 15% of women and transgender men. Current treatments are ineffective for a substantial proportion of patients, underscoring the need for additional therapies with long-term benefits. Nociceptors release neuropeptides, such as calcitonin gene-related peptide (CGRP), which are known to shape immunity through neuroimmune communication.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!